The Loratadine Tablets, cataloged under National Stock Number 6505-01-377-0448, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Mylan Pharmaceuticals Inc. Government technical data includes 6 specifications, cited from the U.S. Government catalog. The record lists 2 manufacturer part numbers for this item, enabling identification through both NSN and commercial part number lookups. 1 additional reference document (drawings, advisory and superseded references) is recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: PG.
| Parameter | Value |
|---|---|
| NSN | 6505-01-377-0448 |
| Primary Part Number | NDC51079-0246-20 |
| Item Name | Loratadine Tablets |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Mylan Pharmaceuticals Inc |
| Status | ACTIVE |
| Therapeutic Equivalent | SCHERING |
| Primary Container Content Quantity | 10.000 TABLETS |
| Features Provided | UNIT DOSE |
| Primary Container Type | CARD |
| Active Medicament Medicinal Strength | 10.000 MILLIGRAMS LORATADINE ACTIVE INGREDIENT |
| Total Primary Container Quantity | 10 |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | PG |
| Part Number | Manufacturer |
|---|---|
| NDC51079-0246-20 PRIMARY | Mylan Pharmaceuticals Inc (USA) |
| NDC00904-7511-61 | The Harvard Drug Group, L.l.c. Dba the Harvard Drug Group, L.l.c Div Major Pharmaceuticals & Rugby Laboratories (USA) |
| Reference | Meaning |
|---|---|
| NDC00904-5793-61 | 5/9 Secondary reference Major Pharmaceuticals Inc |
NSN 6505-01-377-0448 is a Loratadine Tablets, manufactured by Mylan Pharmaceuticals Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-377-0448 has 2 manufacturer part numbers on file: NDC51079-0246-20 (Mylan Pharmaceuticals Inc), NDC00904-7511-61 (The Harvard Drug Group, L.l.c. Dba the Harvard Drug Group, L.l.c Div Major Pharmaceuticals & Rugby Laboratories).
Key specifications for NDC51079-0246-20: Therapeutic Equivalent: SCHERING; Primary Container Content Quantity: 10.000 TABLETS; Features Provided: UNIT DOSE; Primary Container Type: CARD. 6 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.